The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Viral Vector Vaccine for Humans Market Research Report 2025
Synopsis
Viral vaccines are a type of vaccine used to prevent infections caused by viruses. These vaccines increase the body's resistance to a specific virus by causing the immune system to mount an immune response to that virus. Viral vaccines usually contain inactivated, attenuated viruses, their isolated antigens, or their synthetic proteins.
The global Viral Vector Vaccine for Humans market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Viral Vector Vaccine for Humans is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Viral Vector Vaccine for Humans is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Viral Vector Vaccine for Humans include BD, Abbot (Alere), Quidel, Roche, Thermo Fisher Scientific, Meridian Bioscience, Analytik Jena, Princeton BioMeditech Corporation and BioMerieux, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral Vector Vaccine for Humans, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector Vaccine for Humans.
Report Scope
The Viral Vector Vaccine for Humans market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vector Vaccine for Humans market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector Vaccine for Humans manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BD
Abbot (Alere)
Quidel
Roche
Thermo Fisher Scientific
Meridian Bioscience
Analytik Jena
Princeton BioMeditech Corporation
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
DiaSorin (Focus Diagnostics)
Wondfo Biotechnology
Shuo Shi Biology
Biotech
Wantai Biotechnology
Guangzhou Da'an Gene
Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine
Live Vaccine
Segment by Application
Influenza
HPV
Hepatitis B
Measles
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Viral Vector Vaccine for Humans manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Viral Vector Vaccine for Humans in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Viral vaccines are a type of vaccine used to prevent infections caused by viruses. These vaccines increase the body's resistance to a specific virus by causing the immune system to mount an immune response to that virus. Viral vaccines usually contain inactivated, attenuated viruses, their isolated antigens, or their synthetic proteins.
The global Viral Vector Vaccine for Humans market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Viral Vector Vaccine for Humans is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Viral Vector Vaccine for Humans is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Viral Vector Vaccine for Humans include BD, Abbot (Alere), Quidel, Roche, Thermo Fisher Scientific, Meridian Bioscience, Analytik Jena, Princeton BioMeditech Corporation and BioMerieux, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral Vector Vaccine for Humans, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector Vaccine for Humans.
Report Scope
The Viral Vector Vaccine for Humans market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vector Vaccine for Humans market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector Vaccine for Humans manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BD
Abbot (Alere)
Quidel
Roche
Thermo Fisher Scientific
Meridian Bioscience
Analytik Jena
Princeton BioMeditech Corporation
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
DiaSorin (Focus Diagnostics)
Wondfo Biotechnology
Shuo Shi Biology
Biotech
Wantai Biotechnology
Guangzhou Da'an Gene
Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine
Live Vaccine
Segment by Application
Influenza
HPV
Hepatitis B
Measles
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Viral Vector Vaccine for Humans manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Viral Vector Vaccine for Humans in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Viral Vector Vaccine for Humans Market Overview
1.1 Product Overview and Scope of Viral Vector Vaccine for Humans
1.2 Viral Vector Vaccine for Humans Segment by Type
1.2.1 Global Viral Vector Vaccine for Humans Market Value Comparison by Type (2024-2030)
1.2.2 Inactivated Vaccine
1.2.3 Live Attenuated Vaccine
1.2.4 Live Vaccine
1.3 Viral Vector Vaccine for Humans Segment by Application
1.3.1 Global Viral Vector Vaccine for Humans Market Value by Application: (2024-2030)
1.3.2 Influenza
1.3.3 HPV
1.3.4 Hepatitis B
1.3.5 Measles
1.3.6 Others
1.4 Global Viral Vector Vaccine for Humans Market Size Estimates and Forecasts
1.4.1 Global Viral Vector Vaccine for Humans Revenue 2019-2030
1.4.2 Global Viral Vector Vaccine for Humans Sales 2019-2030
1.4.3 Global Viral Vector Vaccine for Humans Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Viral Vector Vaccine for Humans Market Competition by Manufacturers
2.1 Global Viral Vector Vaccine for Humans Sales Market Share by Manufacturers (2019-2024)
2.2 Global Viral Vector Vaccine for Humans Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Viral Vector Vaccine for Humans Average Price by Manufacturers (2019-2024)
2.4 Global Viral Vector Vaccine for Humans Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Viral Vector Vaccine for Humans, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Viral Vector Vaccine for Humans, Product Type & Application
2.7 Viral Vector Vaccine for Humans Market Competitive Situation and Trends
2.7.1 Viral Vector Vaccine for Humans Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Viral Vector Vaccine for Humans Players Market Share by Revenue
2.7.3 Global Viral Vector Vaccine for Humans Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Viral Vector Vaccine for Humans Retrospective Market Scenario by Region
3.1 Global Viral Vector Vaccine for Humans Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Viral Vector Vaccine for Humans Global Viral Vector Vaccine for Humans Sales by Region: 2019-2030
3.2.1 Global Viral Vector Vaccine for Humans Sales by Region: 2019-2024
3.2.2 Global Viral Vector Vaccine for Humans Sales by Region: 2025-2030
3.3 Global Viral Vector Vaccine for Humans Global Viral Vector Vaccine for Humans Revenue by Region: 2019-2030
3.3.1 Global Viral Vector Vaccine for Humans Revenue by Region: 2019-2024
3.3.2 Global Viral Vector Vaccine for Humans Revenue by Region: 2025-2030
3.4 North America Viral Vector Vaccine for Humans Market Facts & Figures by Country
3.4.1 North America Viral Vector Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Viral Vector Vaccine for Humans Sales by Country (2019-2030)
3.4.3 North America Viral Vector Vaccine for Humans Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Viral Vector Vaccine for Humans Market Facts & Figures by Country
3.5.1 Europe Viral Vector Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Viral Vector Vaccine for Humans Sales by Country (2019-2030)
3.5.3 Europe Viral Vector Vaccine for Humans Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Viral Vector Vaccine for Humans Market Facts & Figures by Country
3.6.1 Asia Pacific Viral Vector Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Viral Vector Vaccine for Humans Sales by Country (2019-2030)
3.6.3 Asia Pacific Viral Vector Vaccine for Humans Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Viral Vector Vaccine for Humans Market Facts & Figures by Country
3.7.1 Latin America Viral Vector Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Viral Vector Vaccine for Humans Sales by Country (2019-2030)
3.7.3 Latin America Viral Vector Vaccine for Humans Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Viral Vector Vaccine for Humans Market Facts & Figures by Country
3.8.1 Middle East and Africa Viral Vector Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Viral Vector Vaccine for Humans Sales by Country (2019-2030)
3.8.3 Middle East and Africa Viral Vector Vaccine for Humans Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Viral Vector Vaccine for Humans Sales by Type (2019-2030)
4.1.1 Global Viral Vector Vaccine for Humans Sales by Type (2019-2024)
4.1.2 Global Viral Vector Vaccine for Humans Sales by Type (2025-2030)
4.1.3 Global Viral Vector Vaccine for Humans Sales Market Share by Type (2019-2030)
4.2 Global Viral Vector Vaccine for Humans Revenue by Type (2019-2030)
4.2.1 Global Viral Vector Vaccine for Humans Revenue by Type (2019-2024)
4.2.2 Global Viral Vector Vaccine for Humans Revenue by Type (2025-2030)
4.2.3 Global Viral Vector Vaccine for Humans Revenue Market Share by Type (2019-2030)
4.3 Global Viral Vector Vaccine for Humans Price by Type (2019-2030)
5 Segment by Application
5.1 Global Viral Vector Vaccine for Humans Sales by Application (2019-2030)
5.1.1 Global Viral Vector Vaccine for Humans Sales by Application (2019-2024)
5.1.2 Global Viral Vector Vaccine for Humans Sales by Application (2025-2030)
5.1.3 Global Viral Vector Vaccine for Humans Sales Market Share by Application (2019-2030)
5.2 Global Viral Vector Vaccine for Humans Revenue by Application (2019-2030)
5.2.1 Global Viral Vector Vaccine for Humans Revenue by Application (2019-2024)
5.2.2 Global Viral Vector Vaccine for Humans Revenue by Application (2025-2030)
5.2.3 Global Viral Vector Vaccine for Humans Revenue Market Share by Application (2019-2030)
5.3 Global Viral Vector Vaccine for Humans Price by Application (2019-2030)
6 Key Companies Profiled
6.1 BD
6.1.1 BD Corporation Information
6.1.2 BD Description and Business Overview
6.1.3 BD Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.1.4 BD Viral Vector Vaccine for Humans Product Portfolio
6.1.5 BD Recent Developments/Updates
6.2 Abbot (Alere)
6.2.1 Abbot (Alere) Corporation Information
6.2.2 Abbot (Alere) Description and Business Overview
6.2.3 Abbot (Alere) Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Abbot (Alere) Viral Vector Vaccine for Humans Product Portfolio
6.2.5 Abbot (Alere) Recent Developments/Updates
6.3 Quidel
6.3.1 Quidel Corporation Information
6.3.2 Quidel Description and Business Overview
6.3.3 Quidel Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Quidel Viral Vector Vaccine for Humans Product Portfolio
6.3.5 Quidel Recent Developments/Updates
6.4 Roche
6.4.1 Roche Corporation Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche Viral Vector Vaccine for Humans Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Thermo Fisher Scientific
6.5.1 Thermo Fisher Scientific Corporation Information
6.5.2 Thermo Fisher Scientific Description and Business Overview
6.5.3 Thermo Fisher Scientific Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Thermo Fisher Scientific Viral Vector Vaccine for Humans Product Portfolio
6.5.5 Thermo Fisher Scientific Recent Developments/Updates
6.6 Meridian Bioscience
6.6.1 Meridian Bioscience Corporation Information
6.6.2 Meridian Bioscience Description and Business Overview
6.6.3 Meridian Bioscience Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Meridian Bioscience Viral Vector Vaccine for Humans Product Portfolio
6.6.5 Meridian Bioscience Recent Developments/Updates
6.7 Analytik Jena
6.6.1 Analytik Jena Corporation Information
6.6.2 Analytik Jena Description and Business Overview
6.6.3 Analytik Jena Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Analytik Jena Viral Vector Vaccine for Humans Product Portfolio
6.7.5 Analytik Jena Recent Developments/Updates
6.8 Princeton BioMeditech Corporation
6.8.1 Princeton BioMeditech Corporation Corporation Information
6.8.2 Princeton BioMeditech Corporation Description and Business Overview
6.8.3 Princeton BioMeditech Corporation Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Princeton BioMeditech Corporation Viral Vector Vaccine for Humans Product Portfolio
6.8.5 Princeton BioMeditech Corporation Recent Developments/Updates
6.9 BioMerieux
6.9.1 BioMerieux Corporation Information
6.9.2 BioMerieux Description and Business Overview
6.9.3 BioMerieux Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.9.4 BioMerieux Viral Vector Vaccine for Humans Product Portfolio
6.9.5 BioMerieux Recent Developments/Updates
6.10 Sekisui Diagnostics
6.10.1 Sekisui Diagnostics Corporation Information
6.10.2 Sekisui Diagnostics Description and Business Overview
6.10.3 Sekisui Diagnostics Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sekisui Diagnostics Viral Vector Vaccine for Humans Product Portfolio
6.10.5 Sekisui Diagnostics Recent Developments/Updates
6.11 Response Biomedical
6.11.1 Response Biomedical Corporation Information
6.11.2 Response Biomedical Viral Vector Vaccine for Humans Description and Business Overview
6.11.3 Response Biomedical Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Response Biomedical Viral Vector Vaccine for Humans Product Portfolio
6.11.5 Response Biomedical Recent Developments/Updates
6.12 SA Scientific
6.12.1 SA Scientific Corporation Information
6.12.2 SA Scientific Viral Vector Vaccine for Humans Description and Business Overview
6.12.3 SA Scientific Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.12.4 SA Scientific Viral Vector Vaccine for Humans Product Portfolio
6.12.5 SA Scientific Recent Developments/Updates
6.13 DiaSorin (Focus Diagnostics)
6.13.1 DiaSorin (Focus Diagnostics) Corporation Information
6.13.2 DiaSorin (Focus Diagnostics) Viral Vector Vaccine for Humans Description and Business Overview
6.13.3 DiaSorin (Focus Diagnostics) Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.13.4 DiaSorin (Focus Diagnostics) Viral Vector Vaccine for Humans Product Portfolio
6.13.5 DiaSorin (Focus Diagnostics) Recent Developments/Updates
6.14 Wondfo Biotechnology
6.14.1 Wondfo Biotechnology Corporation Information
6.14.2 Wondfo Biotechnology Viral Vector Vaccine for Humans Description and Business Overview
6.14.3 Wondfo Biotechnology Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Wondfo Biotechnology Viral Vector Vaccine for Humans Product Portfolio
6.14.5 Wondfo Biotechnology Recent Developments/Updates
6.15 Shuo Shi Biology
6.15.1 Shuo Shi Biology Corporation Information
6.15.2 Shuo Shi Biology Viral Vector Vaccine for Humans Description and Business Overview
6.15.3 Shuo Shi Biology Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Shuo Shi Biology Viral Vector Vaccine for Humans Product Portfolio
6.15.5 Shuo Shi Biology Recent Developments/Updates
6.16 Biotech
6.16.1 Biotech Corporation Information
6.16.2 Biotech Viral Vector Vaccine for Humans Description and Business Overview
6.16.3 Biotech Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Biotech Viral Vector Vaccine for Humans Product Portfolio
6.16.5 Biotech Recent Developments/Updates
6.17 Wantai Biotechnology
6.17.1 Wantai Biotechnology Corporation Information
6.17.2 Wantai Biotechnology Viral Vector Vaccine for Humans Description and Business Overview
6.17.3 Wantai Biotechnology Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Wantai Biotechnology Viral Vector Vaccine for Humans Product Portfolio
6.17.5 Wantai Biotechnology Recent Developments/Updates
6.18 Guangzhou Da'an Gene
6.18.1 Guangzhou Da'an Gene Corporation Information
6.18.2 Guangzhou Da'an Gene Viral Vector Vaccine for Humans Description and Business Overview
6.18.3 Guangzhou Da'an Gene Viral Vector Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Guangzhou Da'an Gene Viral Vector Vaccine for Humans Product Portfolio
6.18.5 Guangzhou Da'an Gene Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Viral Vector Vaccine for Humans Industry Chain Analysis
7.2 Viral Vector Vaccine for Humans Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Viral Vector Vaccine for Humans Production Mode & Process
7.4 Viral Vector Vaccine for Humans Sales and Marketing
7.4.1 Viral Vector Vaccine for Humans Sales Channels
7.4.2 Viral Vector Vaccine for Humans Distributors
7.5 Viral Vector Vaccine for Humans Customers
8 Viral Vector Vaccine for Humans Market Dynamics
8.1 Viral Vector Vaccine for Humans Industry Trends
8.2 Viral Vector Vaccine for Humans Market Drivers
8.3 Viral Vector Vaccine for Humans Market Challenges
8.4 Viral Vector Vaccine for Humans Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Viral Vector Vaccine for Humans Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Viral Vector Vaccine for Humans Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Viral Vector Vaccine for Humans Market Competitive Situation by Manufacturers in 2023
Table 4. Global Viral Vector Vaccine for Humans Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Viral Vector Vaccine for Humans Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Viral Vector Vaccine for Humans Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Viral Vector Vaccine for Humans Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Viral Vector Vaccine for Humans Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Viral Vector Vaccine for Humans, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Viral Vector Vaccine for Humans, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Viral Vector Vaccine for Humans, Product Type & Application
Table 12. Global Key Manufacturers of Viral Vector Vaccine for Humans, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Viral Vector Vaccine for Humans by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector Vaccine for Humans as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Viral Vector Vaccine for Humans Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Viral Vector Vaccine for Humans Sales by Region (2019-2024) & (K Units)
Table 18. Global Viral Vector Vaccine for Humans Sales Market Share by Region (2019-2024)
Table 19. Global Viral Vector Vaccine for Humans Sales by Region (2025-2030) & (K Units)
Table 20. Global Viral Vector Vaccine for Humans Sales Market Share by Region (2025-2030)
Table 21. Global Viral Vector Vaccine for Humans Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Viral Vector Vaccine for Humans Revenue Market Share by Region (2019-2024)
Table 23. Global Viral Vector Vaccine for Humans Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Viral Vector Vaccine for Humans Revenue Market Share by Region (2025-2030)
Table 25. North America Viral Vector Vaccine for Humans Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Viral Vector Vaccine for Humans Sales by Country (2019-2024) & (K Units)
Table 27. North America Viral Vector Vaccine for Humans Sales by Country (2025-2030) & (K Units)
Table 28. North America Viral Vector Vaccine for Humans Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Viral Vector Vaccine for Humans Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Viral Vector Vaccine for Humans Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Viral Vector Vaccine for Humans Sales by Country (2019-2024) & (K Units)
Table 32. Europe Viral Vector Vaccine for Humans Sales by Country (2025-2030) & (K Units)
Table 33. Europe Viral Vector Vaccine for Humans Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Viral Vector Vaccine for Humans Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Viral Vector Vaccine for Humans Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Viral Vector Vaccine for Humans Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Viral Vector Vaccine for Humans Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Viral Vector Vaccine for Humans Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Viral Vector Vaccine for Humans Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Viral Vector Vaccine for Humans Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Viral Vector Vaccine for Humans Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Viral Vector Vaccine for Humans Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Viral Vector Vaccine for Humans Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Viral Vector Vaccine for Humans Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Viral Vector Vaccine for Humans Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Viral Vector Vaccine for Humans Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Viral Vector Vaccine for Humans Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Viral Vector Vaccine for Humans Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Viral Vector Vaccine for Humans Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Viral Vector Vaccine for Humans Sales (K Units) by Type (2019-2024)
Table 51. Global Viral Vector Vaccine for Humans Sales (K Units) by Type (2025-2030)
Table 52. Global Viral Vector Vaccine for Humans Sales Market Share by Type (2019-2024)
Table 53. Global Viral Vector Vaccine for Humans Sales Market Share by Type (2025-2030)
Table 54. Global Viral Vector Vaccine for Humans Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Viral Vector Vaccine for Humans Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Viral Vector Vaccine for Humans Revenue Market Share by Type (2019-2024)
Table 57. Global Viral Vector Vaccine for Humans Revenue Market Share by Type (2025-2030)
Table 58. Global Viral Vector Vaccine for Humans Price (US$/Unit) by Type (2019-2024)
Table 59. Global Viral Vector Vaccine for Humans Price (US$/Unit) by Type (2025-2030)
Table 60. Global Viral Vector Vaccine for Humans Sales (K Units) by Application (2019-2024)
Table 61. Global Viral Vector Vaccine for Humans Sales (K Units) by Application (2025-2030)
Table 62. Global Viral Vector Vaccine for Humans Sales Market Share by Application (2019-2024)
Table 63. Global Viral Vector Vaccine for Humans Sales Market Share by Application (2025-2030)
Table 64. Global Viral Vector Vaccine for Humans Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Viral Vector Vaccine for Humans Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Viral Vector Vaccine for Humans Revenue Market Share by Application (2019-2024)
Table 67. Global Viral Vector Vaccine for Humans Revenue Market Share by Application (2025-2030)
Table 68. Global Viral Vector Vaccine for Humans Price (US$/Unit) by Application (2019-2024)
Table 69. Global Viral Vector Vaccine for Humans Price (US$/Unit) by Application (2025-2030)
Table 70. BD Corporation Information
Table 71. BD Description and Business Overview
Table 72. BD Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. BD Viral Vector Vaccine for Humans Product
Table 74. BD Recent Developments/Updates
Table 75. Abbot (Alere) Corporation Information
Table 76. Abbot (Alere) Description and Business Overview
Table 77. Abbot (Alere) Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Abbot (Alere) Viral Vector Vaccine for Humans Product
Table 79. Abbot (Alere) Recent Developments/Updates
Table 80. Quidel Corporation Information
Table 81. Quidel Description and Business Overview
Table 82. Quidel Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Quidel Viral Vector Vaccine for Humans Product
Table 84. Quidel Recent Developments/Updates
Table 85. Roche Corporation Information
Table 86. Roche Description and Business Overview
Table 87. Roche Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Roche Viral Vector Vaccine for Humans Product
Table 89. Roche Recent Developments/Updates
Table 90. Thermo Fisher Scientific Corporation Information
Table 91. Thermo Fisher Scientific Description and Business Overview
Table 92. Thermo Fisher Scientific Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Thermo Fisher Scientific Viral Vector Vaccine for Humans Product
Table 94. Thermo Fisher Scientific Recent Developments/Updates
Table 95. Meridian Bioscience Corporation Information
Table 96. Meridian Bioscience Description and Business Overview
Table 97. Meridian Bioscience Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Meridian Bioscience Viral Vector Vaccine for Humans Product
Table 99. Meridian Bioscience Recent Developments/Updates
Table 100. Analytik Jena Corporation Information
Table 101. Analytik Jena Description and Business Overview
Table 102. Analytik Jena Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Analytik Jena Viral Vector Vaccine for Humans Product
Table 104. Analytik Jena Recent Developments/Updates
Table 105. Princeton BioMeditech Corporation Corporation Information
Table 106. Princeton BioMeditech Corporation Description and Business Overview
Table 107. Princeton BioMeditech Corporation Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Princeton BioMeditech Corporation Viral Vector Vaccine for Humans Product
Table 109. Princeton BioMeditech Corporation Recent Developments/Updates
Table 110. BioMerieux Corporation Information
Table 111. BioMerieux Description and Business Overview
Table 112. BioMerieux Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. BioMerieux Viral Vector Vaccine for Humans Product
Table 114. BioMerieux Recent Developments/Updates
Table 115. Sekisui Diagnostics Corporation Information
Table 116. Sekisui Diagnostics Description and Business Overview
Table 117. Sekisui Diagnostics Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Sekisui Diagnostics Viral Vector Vaccine for Humans Product
Table 119. Sekisui Diagnostics Recent Developments/Updates
Table 120. Response Biomedical Corporation Information
Table 121. Response Biomedical Description and Business Overview
Table 122. Response Biomedical Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Response Biomedical Viral Vector Vaccine for Humans Product
Table 124. Response Biomedical Recent Developments/Updates
Table 125. SA Scientific Corporation Information
Table 126. SA Scientific Description and Business Overview
Table 127. SA Scientific Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. SA Scientific Viral Vector Vaccine for Humans Product
Table 129. SA Scientific Recent Developments/Updates
Table 130. DiaSorin (Focus Diagnostics) Corporation Information
Table 131. DiaSorin (Focus Diagnostics) Description and Business Overview
Table 132. DiaSorin (Focus Diagnostics) Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. DiaSorin (Focus Diagnostics) Viral Vector Vaccine for Humans Product
Table 134. DiaSorin (Focus Diagnostics) Recent Developments/Updates
Table 135. Wondfo Biotechnology Corporation Information
Table 136. Wondfo Biotechnology Description and Business Overview
Table 137. Wondfo Biotechnology Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Wondfo Biotechnology Viral Vector Vaccine for Humans Product
Table 139. Wondfo Biotechnology Recent Developments/Updates
Table 140. Shuo Shi Biology Corporation Information
Table 141. Shuo Shi Biology Description and Business Overview
Table 142. Shuo Shi Biology Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Shuo Shi Biology Viral Vector Vaccine for Humans Product
Table 144. Shuo Shi Biology Recent Developments/Updates
Table 145. Biotech Corporation Information
Table 146. Biotech Description and Business Overview
Table 147. Biotech Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Biotech Viral Vector Vaccine for Humans Product
Table 149. Biotech Recent Developments/Updates
Table 150. Wantai Biotechnology Corporation Information
Table 151. Wantai Biotechnology Description and Business Overview
Table 152. Wantai Biotechnology Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Wantai Biotechnology Viral Vector Vaccine for Humans Product
Table 154. Wantai Biotechnology Recent Developments/Updates
Table 155. Guangzhou Da'an Gene Corporation Information
Table 156. Guangzhou Da'an Gene Description and Business Overview
Table 157. Guangzhou Da'an Gene Viral Vector Vaccine for Humans Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Guangzhou Da'an Gene Viral Vector Vaccine for Humans Product
Table 159. Guangzhou Da'an Gene Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Viral Vector Vaccine for Humans Distributors List
Table 163. Viral Vector Vaccine for Humans Customers List
Table 164. Viral Vector Vaccine for Humans Market Trends
Table 165. Viral Vector Vaccine for Humans Market Drivers
Table 166. Viral Vector Vaccine for Humans Market Challenges
Table 167. Viral Vector Vaccine for Humans Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Viral Vector Vaccine for Humans
Figure 2. Global Viral Vector Vaccine for Humans Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Viral Vector Vaccine for Humans Market Share by Type in 2023 & 2030
Figure 4. Inactivated Vaccine Product Picture
Figure 5. Live Attenuated Vaccine Product Picture
Figure 6. Live Vaccine Product Picture
Figure 7. Global Viral Vector Vaccine for Humans Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Viral Vector Vaccine for Humans Market Share by Application in 2023 & 2030
Figure 9. Influenza
Figure 10. HPV
Figure 11. Hepatitis B
Figure 12. Measles
Figure 13. Others
Figure 14. Global Viral Vector Vaccine for Humans Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Viral Vector Vaccine for Humans Market Size (2019-2030) & (US$ Million)
Figure 16. Global Viral Vector Vaccine for Humans Sales (2019-2030) & (K Units)
Figure 17. Global Viral Vector Vaccine for Humans Average Price (US$/Unit) & (2019-2030)
Figure 18. Viral Vector Vaccine for Humans Report Years Considered
Figure 19. Viral Vector Vaccine for Humans Sales Share by Manufacturers in 2023
Figure 20. Global Viral Vector Vaccine for Humans Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest Viral Vector Vaccine for Humans Players: Market Share by Revenue in 2023
Figure 22. Viral Vector Vaccine for Humans Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global Viral Vector Vaccine for Humans Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Viral Vector Vaccine for Humans Sales Market Share by Country (2019-2030)
Figure 25. North America Viral Vector Vaccine for Humans Revenue Market Share by Country (2019-2030)
Figure 26. United States Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Viral Vector Vaccine for Humans Sales Market Share by Country (2019-2030)
Figure 29. Europe Viral Vector Vaccine for Humans Revenue Market Share by Country (2019-2030)
Figure 30. Germany Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Netherlands Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Viral Vector Vaccine for Humans Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Viral Vector Vaccine for Humans Revenue Market Share by Region (2019-2030)
Figure 37. China Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. China Taiwan Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Australia Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Viral Vector Vaccine for Humans Sales Market Share by Country (2019-2030)
Figure 45. Latin America Viral Vector Vaccine for Humans Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Viral Vector Vaccine for Humans Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Viral Vector Vaccine for Humans Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Viral Vector Vaccine for Humans Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Viral Vector Vaccine for Humans by Type (2019-2030)
Figure 55. Global Revenue Market Share of Viral Vector Vaccine for Humans by Type (2019-2030)
Figure 56. Global Viral Vector Vaccine for Humans Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Viral Vector Vaccine for Humans by Application (2019-2030)
Figure 58. Global Revenue Market Share of Viral Vector Vaccine for Humans by Application (2019-2030)
Figure 59. Global Viral Vector Vaccine for Humans Price (US$/Unit) by Application (2019-2030)
Figure 60. Viral Vector Vaccine for Humans Value Chain
Figure 61. Viral Vector Vaccine for Humans Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
